MK-677 vs CJC-1295
Oral non-peptide GH secretagogue vs injectable GHRH analogue — comparing two fundamentally different approaches to sustained growth hormone elevation.
Last updated: 2026-03-08
Quick Comparison Table
| Category | MK-677 | CJC-1295 |
|---|---|---|
| Molecule Type | Non-peptide small molecule (spiroindoline) | Peptide (modified GHRH 1-29) |
| Receptor Target | Ghrelin receptor (GHS-R1a) | GHRH receptor (GRF) |
| Administration | Oral (once daily) | SC injection (1-3x daily or weekly with DAC) |
| Duration of Action | ~24 hours (single daily dose) | Without DAC: 30 min; with DAC: 6-8 days |
| GH Release Pattern | Sustained elevation (pulsatile preserved) | Without DAC: acute pulse; with DAC: sustained |
| IGF-1 Elevation | 40-89% increase sustained over months | 35-65% increase (DAC version) |
| Appetite Effect | Strong increase (ghrelin receptor) | None |
| Key Advantage | Oral convenience, no injection | Synergy with GHRPs, no appetite increase |
Mechanism of Action
MK-677
MK-677 (Ibutamoren) Mechanism:
MK-677 is a non-peptide ghrelin receptor agonist — a small molecule that mimics ghrelin's GH-releasing activity without being a peptide.
Key actions: 1. **GHS-R1a agonism** — Stimulates GH release from pituitary, mimicking ghrelin 2. **Sustained GH/IGF-1 elevation** — 24-hour duration maintains elevated GH and IGF-1 with once-daily dosing 3. **Preserved pulsatility** — Despite sustained elevation, natural GH pulse pattern is maintained 4. **Appetite stimulation** — Strong ghrelin-like hunger effect 5. **No desensitisation** — Maintains efficacy for months to years without cycling
MK-677's oral bioavailability is its key differentiator — it's the only orally active GH secretagogue with sustained efficacy.
CJC-1295
CJC-1295 Mechanism:
CJC-1295 is a synthetic GHRH analogue — modified GRF(1-29) with amino acid substitutions for protease resistance.
Available in two forms: - **Without DAC (Mod GRF 1-29):** Short-acting (~30 min half-life), produces acute GH pulses - **With DAC (Drug Affinity Complex):** Long-acting (6-8 day half-life), sustained GH/IGF-1 elevation via albumin binding
Key actions: 1. **GHRH receptor activation** — Stimulates GH release through the physiological GHRH pathway 2. **Synergy with GHRPs** — Combines with ghrelin receptor agonists for amplified GH release 3. **No appetite effect** — Does not activate ghrelin/hunger pathways 4. **IGF-1 elevation** — Sustained increase with DAC version
Clinical Trial Evidence
MK-677 Clinical Studies
Design: Randomised controlled trial
Participants: 416 participants
Duration: 12 months
Despite evidence of target engagement as indicated by an increase in serum insulin-like growth factor-1, the human growth hormone secretagogue MK-677 25 mg was ineffective at slowing the rate of progression of Alzheimer disease.
View study — PubMed 19015485Design: Randomised controlled trial
The proportion of 20K GH in 2-h samples after the initial MK-677 administration was lower than that after 2 and 8 weeks. These moderate changes in the proportion non-22K GH isoforms are likely of small importance for the clinical response to MK-677 treatment.
View study — PubMed 12550076Design: Randomised controlled trial
Participants: 292 participants
Duration: 12 months
In conclusion, the anabolic effect of GH, as produced through the GH secretagogue MK-677, attenuated the indirect suppressive effect of alendronate on bone formation, but did not translate into significant increases in BMD at sites other than the femoral neck.
View study — PubMed 11238495Design: Randomised controlled trial
Participants: 12 participants
Duration: 8 weeks
At study end, the LDL-C/HDL-C ratio was decreased. MK-677 treatment did not significantly affect serum Lp(a) concentrations at the present dose and administration protocol.
View study — PubMed 10372705CJC-1295 Clinical Studies
Design: Randomised controlled trial
Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.
View study — PubMed 16352683Design: Clinical trial
CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory capability.
View study — PubMed 17018654Design: Review
While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.
View study — PubMed 41476424Design: Review
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
View study — PubMed 41880199Benefits Comparison
MK-677 Unique Benefits
- Oral administration — no injection
- Once-daily dosing convenience
- Sustained 24-hour GH/IGF-1 elevation
- No desensitisation with long-term use
- Improved deep sleep quality
Shared Benefits
- Sustained IGF-1 elevation
- GH axis stimulation
- Body composition improvement
- Bone density benefits
- Preserved GH pulsatility
CJC-1295 Unique Benefits
- No appetite stimulation
- Synergistic with GHRPs (Ipamorelin, GHRP-2)
- More physiological GH pulsatility (Mod GRF)
- No glucose/insulin effects
- Weekly dosing option (DAC version)
Research & Evidence
MK-677 Research
MK-677 has a robust clinical evidence base — 2-year studies in elderly, bone density trials in postmenopausal women, and body composition studies. Its pharmacology is well-characterised. Despite not achieving FDA approval, its evidence base is substantial.
CJC-1295 Research
CJC-1295's evidence is primarily Phase I/II pharmacokinetic and dose-response data. The DAC formulation demonstrated sustained GH/IGF-1 elevation but clinical development stalled. Most practical evidence comes from combination use with Ipamorelin in the research peptide community.
Head-to-Head Analysis
Different Receptors, Different Approaches:
MK-677 and CJC-1295 stimulate GH through different receptors — ghrelin (MK-677) vs GHRH (CJC-1295). This means:
1. They are synergistic, not competitive (can be combined) 2. Each has receptor-specific side effects (appetite for MK-677, none for CJC-1295) 3. MK-677 does not require co-administration with a GHRP (it IS the ghrelin component)
Practical Comparison: MK-677 offers oral convenience and once-daily dosing. CJC-1295 (without DAC) requires 2-3x daily injection but produces cleaner GH pulses without appetite stimulation. CJC-1295 DAC offers weekly injection but with continuous (non-pulsatile) GH stimulation that some consider less physiological.
IGF-1 Elevation: Both sustainably elevate IGF-1. MK-677 studies show 40-89% increase maintained for 12+ months. CJC-1295 DAC shows 35-65% increase.
Protocol Comparison
MK-677 Protocol
MK-677 Protocols:
Dosing: 10-25mg oral once daily. 25mg most studied. Timing: Bedtime (to maximise sleep GH release) or morning. Duration: Can be used continuously for months-years without cycling.
⚠️ Note: Monitor fasting glucose and insulin. Appetite increase is significant.
CJC-1295 Protocol
CJC-1295 Protocols:
Without DAC (Mod GRF 1-29): 100mcg SC, 2-3x daily. Best combined with GHRP (e.g., Ipamorelin 100-200mcg).
With DAC: 1-2mg SC weekly. Produces continuous GH/IGF-1 elevation.
⚠️ Note: Mod GRF requires reconstitution and injection. DAC version weekly.
Safety Profiles
MK-677 Safety
MK-677 Safety:
Common: Increased appetite (significant), water retention/oedema, muscle cramps, joint pain. Fasting glucose elevation at 25mg dose — insulin resistance possible with long-term use.
Monitor: Blood glucose, HbA1c, insulin levels, especially in pre-diabetics.
Well-tolerated over 2 years in elderly study. No serious drug-related adverse events.
CJC-1295 Safety
CJC-1295 Safety:
Without DAC: Very well-tolerated. Injection site reactions, transient flushing, headache.
With DAC: Similar profile. One death reported in early clinical trials (cause debated — possibly unrelated). This incident contributed to stalled clinical development.
No glucose, insulin, or appetite effects — cleaner metabolic profile than MK-677.
The Verdict
MK-677's oral convenience and sustained efficacy without desensitisation make it uniquely practical for long-term GH optimisation. CJC-1295's advantage is its clean metabolic profile (no appetite, no glucose effects) and synergistic combination with GHRPs. The choice often depends on priorities: convenience and monotherapy (MK-677) vs clean physiology and combination potential (CJC-1295). Many researchers note that MK-677 and CJC-1295 target different receptors and can theoretically be combined for synergistic GH release.
Frequently Asked Questions
Conclusion
MK-677 and CJC-1295 represent two complementary pathways to GH axis stimulation — oral ghrelin mimicry vs injectable GHRH analogue. MK-677's unique oral bioavailability, once-daily dosing, and lack of desensitisation make it the most practical long-term GH secretagogue. CJC-1295's clean metabolic profile and GHRP synergy make it the preferred injectable option. Understanding their different receptor targets reveals why they are often discussed as complementary rather than competing approaches.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither MK-677 nor CJC-1295 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.